Restricted accessResearch articleFirst published online 2021-11
Factors associated with self-reported adherence to daily oral pre-exposure prophylaxis among men who have sex with man and transgender women: PrEP Brasil study
Understanding the factors associated with pre-exposure prophylaxis (PrEP) adherence may help in the development of strategies to support, motivate and sustain PrEP use. This study estimated self-reported adherence, described perceived barriers and facilitators and investigated factors associated with adherence to daily oral PrEP among men who have sex with man (MSM) and transgender women after 1 year of PrEP use in Brazil. PrEP Brasil was a prospective, multicentre, open-label demonstration study with MSM and transgender women at high risk for HIV infection. We used logistic regression to evaluate factors associated with complete adherence (not forgetting to take any pills in the past 30 days) at week 48. Of 338 participants included in this analysis, 60% reported complete adherence to daily oral PrEP at week 48. Perceived barriers and facilitators to daily oral PrEP were reported by 38.2% and 98.5%, respectively. The most reported barrier and facilitator were ‘I forgot to take my pills’ (19.2%) and ‘Associate PrEP with a daily activity/task’ (58.6%), respectively. In final multivariable analysis, living in Rio de Janeiro (aOR: 0.38; 95% CI: 0.20–0.73), being transgender women (aOR: 0.22; 95% CI: 0.07–0.73), reporting stimulant use (a OR: 0.40; 95% CI: 0.20–0.80) and having any perceived barriers to daily oral PrEP (aOR: 0.12; 95% CI: 0.07–0.23) were associated with decreased odds of complete adherence. Our findings provide information for developing the best practices to promote PrEP adherence in the Brazilian context.
GrantRMLamaJRAndersonPL, et al.Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med2010; 363: 2587–2599.
2.
MolinaJMCapitantCSpireB, et al.On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med2015; 373: 2237–2246.
3.
McCormackSDunnDTDesaiM, et al.Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet2016; 387: 53–60.
4.
GandhiMGliddenDVLiuA, et al.Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried blood spots in the iPrEx open label extension: implications for pre-exposure prophylaxis adherence monitoring. J Infect Dis2015; 212: 1402–1406.
5.
AndersonPLGliddenDVLiuA, et al.Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med2012; 4: 151ra125.
6.
GrantRMAndersonPLMcMahanV, et al.Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis2014; 14: 820–829.
7.
LiuAYYangQHuangY, et al.Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One2014; 9: e83736.
8.
HabererJEBangsbergDRBaetenJM, et al.Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS2015; 29: 1277–1285.
9.
HabererJE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS2016; 11: 10–17.
10.
AmicoKR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS2012; 7: 542–548.
11.
CostaJdMTorresTSCoelhoLE, et al.Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean: systematic review and meta-analysis. J Intern AIDS Soc2018; 21: e25066.
12.
AmicoKRMehrotraMAvelino-SilvaVI, et al.Self-reported recent PrEP dosing and drug detection in an open label PrEP study. AIDS Behav2016; 20: 1535–1540.
13.
KebaabetswePMStirrattMJMcLellan-LemalE, et al.Factors associated with adherence and concordance between measurement strategies in an HIV daily oral tenofovir/emtricitibine as pre-exposure prophylaxis (Prep) clinical trial, Botswana, 2007-2010. AIDS Behav2015; 19: 758–769.
14.
MarinsLMSTorresTSLeiteIDC, et al.Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: results from the PrEP Brasil study. PLOS One2019; 14: e0221281.
15.
MitchellJTLeGrandSHightow-WeidmanLB, et al.Smartphone-based contingency management intervention to improve pre-exposure prophylaxis adherence: pilot trial. JMIR MHealth UHealth2018; 6: e10456.
16.
BaxiSMLiuABacchettiP, et al.Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr2015; 68: 13–20.
17.
CorneliALDeeseJWangM, et al.FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr2014; 66: 324–331.
18.
SidebottomDEkströmAMStrömdahlS. A systematic review of adherence to oral pre-exposure prophylaxis for HIV–how can we improve uptake and adherence?BMC Infect Dis2018; 18: 581.
19.
GilmoreHJLiuAKoesterKA, et al.Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDs2013; 27: 560–566.
20.
TaylorSWPsarosCPantaloneDW, et al.“Life-Steps” for PrEP adherence: demonstration of a CBT-based intervention to increase adherence to preexposure prophylaxis (PrEP) medication among sexual-minority men at high risk for HIV acquisition. Cogn Behav Pract2017; 24: 38–49.
21.
BlashillAJEhlingerPPMayerKH, et al.Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach. Clin Infect Dis2015; 60(Suppl 3): S187–S190.
22.
ClossonEFMittyJAMaloneJ, et al.Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. AIDS Care2018; 30: 191–198.
23.
HannafordALipshie-WilliamsMStarrelsJL, et al.The use of online posts to identify barriers to and facilitators of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men: a comparison to a systematic review of the peer-reviewed literature. AIDS Behav2018; 22: 1080–1095.
24.
TorresTSKondaKAVega-RamirezEH, et al.Factors associated with willingness to use pre-exposure prophylaxis in Brazil, Mexico, and Peru: web-based survey among men who have sex with men. JMIR Public Health Surveill2019; 5: e13771.
25.
GrinsztejnBHoaglandBMoreiraRI, et al.Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV2018; 5: e136–e145.
26.
HoaglandBMoreiraRIDe BoniRB, et al.High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc2017; 20: 21472.
27.
LuzPMVelosoVGGrinsztejnB. The HIV epidemic in Latin America: accomplishments and challenges on treatment and prevention. Curr Opin HIV AIDS2019; 14: 366–373.
28.
VelosoVGVega-RamirezEHHoaglandB, et al.Safety, early continuation and adherence of same day PrEP initiation among MSM and TGW in Brazil, Mexico and Peru: the ImPrEP Study [TUAC0404LB], 2019. http://programme.ias2019.org/Abstract/Abstract/4894
LuzPMBenzakenAAlencarTM, et al.PrEP adopted by the brazilian national health system: what is the size of the demand?Medicine (Baltimore)2018; 97: S75–S77.
de Lima OsórioFVilela MendesACrippaJA, et al.Study of the discriminative validity of the PHQ-9 and PHQ-2 in a sample of Brazilian women in the context of primary health care. Perspect Psychiatr Care2009; 45: 216–227.
33.
KroenkeKSpitzerRLWilliamsJB. The patient health questionnaire-2: validity of a two-item depression screener. Med Care2003; 41: 1284–1292.
34.
NagelkerkeNJD. A note on a general definition of the coefficient of determination. Biometrika1991; 78: 691–692.
35.
CoelhoLETorresTSVelosoVG, et al.The prevalence of HIV among men who have sex with men (MSM) and young MSM in Latin America and the Caribbean: a systematic review. AIDS Behav. Epub ahead of print 15 February 2021. DOI: 10.1007/s10461-021-03180-5.
36.
GrinsztejnBJalilEMMonteiroL, et al.Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil. Lancet HIV2017; 4: e169–e176.
37.
CoelhoLETorresTSVelosoVG, et al.Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV2019; 6: e788–e799.
38.
ChangSJChoiSKimS-A, et al.Intervention strategies based on information-motivation-behavioral skills model for health behavior change: a systematic review. Asian Nurs Res2014; 8: 172–181.
39.
LiuAYCohenSEVittinghoffE, et al.Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med2016; 176: 75–84.
40.
MontgomeryMCOldenburgCENunnAS, et al.Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLOS One2016; 11: e0157742.
41.
MusinguziNMuganziCDBoumY, et al.Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS2016; 30: 1121–1129.
42.
HabererJEBaetenJMCampbellJ, et al.Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. Plos Med2013; 10: e1001511.
43.
AmicoKRMcMahanVGoicocheaP, et al.Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav2012; 16: 1243–1259.
44.
AmicoKRMillerJBalthazarC, et al.Integrated next step counseling (iNSC) for sexual health and PrEP use among young men who have sex with men: implementation and observations from ATN110/113. AIDS Behav. Epub ahead of print 9 October 2018. DOI: 10.1007/s10461-018-2291-2.
45.
HosekSGRudyBLandovitzR, et al.An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr2017; 74: 21–29.
46.
TorresTSBastosLSKamelL, et al.Do men who have sex with men who report alcohol and illicit drug use before/during sex (chemsex) present moderate/high risk for substance use disorders?. Drug Alcohol Depend2020; 209: 107908.
47.
HoeniglMHassanAMooreDJ, et al.Predictors of long-term HIV pre-exposure prophylaxis adherence after study participation in men who have sex with men. J Acquir Immune Defic Syndr2019; 81: 166–174.
48.
LatalovaKKamaradovaDPraskoJ. Perspectives on perceived stigma and self-stigma in adult male patients with depression. Neuropsychiatr Dis Treat2014; 10: 1399–1405.
49.
SeekaewPNguyenESungsingT, et al.Correlates of nonadherence to key population-led HIV pre-exposure prophylaxis services among Thai men who have sex with men and transgender women. BMC Public Health2019; 19: 328.
50.
WilsonEC.TurnerC. M.ArayasirikulS., et al.Disparities in the PrEP continuum for trans women compared to MSM in San Francisco, California: results from population‐based cross‐sectional behavioural surveillance studies. J Intern AIDS Soc. Epub ahead of print June 2020. DOI: 10.1002/jia2.25539.
51.
Garcia FerreiraACEsteves CoelhoLJalilEM, et al.Transcendendo: a cohort study of HIV-infected and uninfected transgender women in Rio de Janeiro, Brazil. Transgender Health2019; 4: 107–117.
52.
AmicoKRMarcusJLMcMahanV, et al.Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr2014; 66: 530–537.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
